Endothelial inflammatory signaling

Endothelial inflammatory signaling is a coordinated biological process involving multiple intracellular pathways that regulate the vascular endothelium's response to injury and inflammation [1.2.1, 1.3.1]. Triggered by stimuli such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and lipopolysaccharide (LPS), this signaling primarily converges on the activation of the NF-κB and MAPK pathways [1.3.3, 1.3.4]. Activation leads to the upregulation of endothelial-leukocyte adhesion molecules, including ICAM-1, VCAM-1, and E-selectin, and the secretion of chemokines like MCP-1, which facilitate the recruitment and extravasation of immune cells into the vessel wall [1.2.1, 1.3.4]. While essential for host defense, chronic or excessive endothelial inflammatory signaling is a primary driver of endothelial dysfunction, contributing to the development of atherosclerosis, hypertension, and sepsis [1.1.3, 1.2.4]. Pharmacological modulation of these pathways, through agents like statins or cytokine inhibitors, aims to restore vascular homeostasis and prevent the progression of inflammatory cardiovascular diseases [1.1.2, 1.3.5]. Emerging research also explores targeted delivery systems to specifically inhibit these signals within the inflamed vasculature to minimize systemic side effects [1.4.1, 1.4.3].

Other names

Endothelial activationEndothelial proinflammatory signalingVascular inflammatory signalingEndothelial dysfunction signaling

Inhibition of NF-kappaB and MAPK signaling pathways, suppression of adhesion molecule expression (ICAM-1, VCAM-1, E-selectin), and reduction of proinflammatory cytokine production.